The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-23 and is reviewed periodically as new material appears.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Clematis addisonii Britt. – Addison's leather flower Clematis akebioides (Maxim.) H.J.Veitch Clematis albicoma Wherry – whitehair leather flower Clematis alpina (L.) Mill. – alpine clematis Clematis aristata R.Br. ex Ker Gawl. – Australian clematis Clematis armandii – Armand clematis Clematis baldwinii Torr. & A.Gray – pine hyacinth Clematis bigelovii Torr. – Bigelow clematis Clematis brachiata Thunb. – traveller's joy Clematis campaniflora Brot. – Portuguese clematis Clematis catesbyana – satin curls Clematis chinensis Osbeck – wei ling xian in Chinese (Chinese: 威靈仙; pinyin: Wei ling xian) Clematis chrysocoma Franch. – gold wool clematis Clematis cirrhosa L. – includes the 'Freckles', 'Wisley Cream', and 'Jingle Bells' cultivars Clematis cirrhosa v. balearica (Balearic Islands) Clematis coactilis (Fern.) Keener – Virginia whitehair leather flower Clematis columbiana (Nutt.) Torr. & A.Gray – British Columbia virgin's bower Clematis crispa L. – swamp leather flower Clematis cunninghamii Clematis dioica L. – cabellos de angel Clematis drummondii Torr. & A.Gray – Drummond clematis Clematis durandii Clematis fawcettii F.Muell. Clematis flammula L. – fragrant virgin's bower Clematis florida Thunb. – Asian clematis Clematis foetida Raoul (1846) – New Zealand clematis Clematis fremontii S.Watson – Fremont's leather flower Clematis glaucophylla Small – whiteleaf leather flower Clematis glycinoides DC. – headache vine Clematis gouriana – Indian traveller's joy Clematis henryi Oliv. Clematis hirsutissima Pursh – hairy clematis Clematis hedysarifolia DC. Clematis integrifolia L.
Lee Limbird (born November 27, 1948, in Philadelphia, Pennsylvania) is a pharmacologist, Dean of the School of Natural Science, Mathematics and Business & Professor in the Department of Life and Physical Sciences at Fisk University, Nashville, Tennessee. Limbird has been recognized for "outstanding scientific contributions in research and mentoring in pharmacology", in particular her "pioneering research on alpha-2 adrenergic receptors and how they relate to the regulation of blood pressure, sedation, pain suppression and opioid drug action". Among other awards, she received the Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET) in 2013.
In 2000, the NHTSA released a regulation making trunk releases mandatory for new cars by September of the following year due, in part, to the lobbying efforts of Janette Fennell. In 2003, the IIHS began conducting side impact crash tests. In 2004, NHTSA released new tests designed to test the rollover risk of new cars and SUVs. Only the Mazda RX-8 got a 5-star rating. Also in 2003, the National Highway Traffic Safety Administration (NHTSA) introduced a female counterpart crash test dummy of Hybrid III. This dummy was just a scaled-down version of the original Hybrid III, only representing the smallest 5% of women based on mid-1970s standards. In 2009, Citroën became the first manufacturer to feature "Snowmotion", an Intelligent Anti Skid system developed in conjunction with Bosch, which gives drivers a level of control in extreme ice or snow conditions similar to a 4x4. In 2009, NHTSA upgraded its roof-crush standard for vehicles weighing 6000 pounds or less. The new standard increased the crush load requirement from 1.5 to 3 times the vehicle's curb weight.
Owing to the presence of d-shell, uranium (as well as many other actinides) forms organometallic compounds, such as UIII(C5H5)3 and UIV(C5H5)4. Neptunium has valence states from 3 to 7, which can be simultaneously observed in solutions. The most stable state in solution is +5, but the valence +4 is preferred in solid neptunium compounds. Neptunium metal is very reactive. Ions of neptunium are prone to hydrolysis and formation of coordination compounds. Plutonium also exhibits valence states between 3 and 7 inclusive, and thus is chemically similar to neptunium and uranium. It is highly reactive, and quickly forms an oxide film in air. Plutonium reacts with hydrogen even at temperatures as low as 25–50 °C; it also easily forms halides and intermetallic compounds. Hydrolysis reactions of plutonium ions of different oxidation states are quite diverse. Plutonium(V) can enter polymerization reactions. The largest chemical diversity among actinides is observed in americium, which can have valence between 2 and 6. Divalent americium is obtained only in dry compounds and non-aqueous solutions (acetonitrile). Oxidation states +3, +5 and +6 are typical for aqueous solutions, but also in the solid state. Tetravalent americium forms stable solid compounds (dioxide, fluoride and hydroxide) as well as complexes in aqueous solutions. It was reported that in alkaline solution americium can be oxidized to the heptavalent state, but these data proved erroneous. The most stable valence of americium is 3 in aqueous solution and 3 or 4 in solid compounds.
The findings were published after President Trump and Kennedy both claimed that paracetamol use during pregnancy was contributing to rising autism rates, urging women to avoid the common painkiller. Health experts and the World Health Organization rejected those claims, emphasizing that paracetamol remains the safest recommended medication for fever and pain relief during pregnancy, as untreated fever can pose serious risks to fetal development. Acetaminophen and paracetamol are the identical chemical drug compound. The name acetaminophen (brand name Tylenol) is commonly used in the United States while the name paracetamol (brand name Panadol) is commonly used in Europe and world wide.
Sources: en.wikipedia.org
** Indicates an Imperial Fortress † Bermuda and Halifax were linked, under the Commander-in-Chief at Halifax, with units and strength at Bermuda included in figures for Halifax In February 1855 the new Secretary of State for War was additionally commissioned as Secretary at War, thus giving the Secretary of State oversight of the War Office in addition to his own department. The same procedure was followed for each of his successors, until the office of Secretary at War was abolished altogether in 1863. In 1855 the Board of Ordnance was abolished as a result of its perceived poor performance during the Crimean War. This powerful independent body, dating from the 15th century, had been directed by the Master-General of the Ordnance, usually a very senior military officer who (unlike the Secretary at War) was often a member of the Cabinet. The disastrous campaigns of the Crimean War resulted in the consolidation of all administrative duties in 1855 as subordinate to the Secretary of State for War, a Cabinet job. He was not, however, solely responsible for the Army; the Commander-in-Chief had a virtually equal degree of responsibility. This was reduced in theory by the reforms introduced by Edward Cardwell in 1870, which subordinated the Commander-in-Chief to the Secretary for War. In practice, however, a large influence was retained by the conservative Commander-in-Chief Field Marshal Prince George, 2nd Duke of Cambridge, who held the post between 1856 and 1895.
=== Rare causes of cholestasis === The causes of cholestasis are diverse, and some feature more prominently than others. Some rare causes include primary sclerosing cholangitis, primary biliary cholangitis, familial intrahepatic cholestasis, Alagille syndrome, sepsis, total parenteral nutrition-based cholestasis, benign recurrent intrahepatic cholestasis, biliary atresia, and intrahepatic cholestasis of pregnancy.
== TGF-β mimic == The parasitic roundworm Heligmosomoides polygyrus secretes a molecule that mimics the ability of mammalian TGF-β to bind to the TGFβR complex and trigger downstream signalling pathways. This molecule, termed Hp-TGM, shares no sequence homology to TGF-β and is secreted by H. polygyrus in a biologically active form. Hp-TGM consists of 5 domains, with the first three shown to crucial for interaction with the TGFβR complex, with functions for domains 4 and 5 not yet known. Importantly, Hp-TGM shows promise as a novel therapeutic as it induces less fibrosis than TGF-β in vivo in mice and can be used to induce populations of human FOXP3+ regulatory T cells that had much greater stability than those induced by TGF-β.
A syndesmosis (“fastened with a band”) is a type of fibrous joint in which two bones are united to each other by fibrous connective tissue. The gap between the bones may be narrow, with the bones joined by ligaments, or the gap may be wide and filled in by a broad sheet of connective tissue called an interosseous membrane. The syndesmoses found in the forearm and leg serve to unite parallel bones and prevent their separation.
== References == Cooper, Paul W. (1996). Explosives Engineering. New York: Wiley-VCH. ISBN 978-0-471-18636-6. OCLC 34409473. Retrieved 9 June 2014. Urbanski, Tadeusz (1967). Chemistry and Technology of Explosives. Vol. III. Warszawa: Polish Scientific Publishers.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.